PsyAccess introduces a registry-checked catalog of authorized ketamine- and psychedelic-assisted therapy practitioners across 27 European countries.
PsyAccess represents the patient-oriented dimension of our conviction that this sector advances through credibility, not sensationalism.”— Iurii Filatov, Co-Founder & CEO, Pink Elephant GroupLISBON, PORTUGAL, September 17, 2026 /EINPresswire.com/ — Despite being a therapeutic category that frequently dominates headlines, approved esketamine and ketamine treatment, active clinical trials, and sanctioned psychedelic-assisted therapy remain surprisingly difficult to access across Europe. The relevant details are dispersed throughout 27 distinct regulatory frameworks and a dozen languages, clinic promotional material sits side-by-side with objective information, and when someone queries an AI assistant for guidance, no dependable reference has existed for it to draw upon. PsyAccess, debuting today, provides the solution: a complimentary catalog featuring 487 licensed and registry-verifiable entries spanning 27 nations, with the original source link displayed directly on each listing.
Inclusion confirms that licensing and factual assertions are checked against official registries, but never assesses clinical quality, effectiveness, or the therapy itself. PsyAccess does not rank practitioners.
What the catalog immediately reveals is how disparate access truly is. Of the 103 providers cleared to deliver psychedelic-assisted therapy in the strictest sense, 101 are clinicians operating under Switzerland’s individual-patient authorization framework, and 2 are German facilities involved in an authorized psilocybin compassionate-use initiative (BfArM, §3 BtMG). Every other country featured in the directory has zero. Seven nations — Cyprus, Estonia, Latvia, Lithuania, Malta, Romania, and Slovakia — have only one confirmed provider of any type. “Legal” and “accessible,” it emerges, carry vastly different implications depending on where a patient resides.
What distinguishes this directory is not merely its existence, but its construction. In a sector where clinic advertising often blurs into fact, and US-style directories feature whoever compensates them, PsyAccess takes nearly the opposite approach. Being listed is free, and no form of payment influences whether a provider is included, its position, or how its entry is vetted. Every entry demands at least two separate sources — the benchmark a news organization applies to a claim — and whenever a public registry exists, one of those sources must be that registry. A listing that cannot satisfy this threshold is not quietly tagged as “unconfirmed.” It is removed, and it remains delisted until it can be substantiated once more.
The pathways are not equivalent, and the directory distinguishes them: 212 licensed esketamine facilities, 129 clinical trial locations, 103 approved psychedelic-assisted therapy providers, and 43 ketamine or ketamine-assisted psychotherapy practices. Of the 129 trial sites, involvement constitutes research under a study protocol, not a type of accessible clinical treatment. Counting only the pathways through which a patient can genuinely receive care, the catalog lists 358 providers, not 487.
“PsyAccess is the patient-facing element of our belief that this field progresses through trust, not hype. Every entry connects to an official registry, and anything we cannot verify, we remove rather than embellish. PsyAccess is part of Pink Elephant Group, and it earns that trust by functioning autonomously from everything else we do.”
Iurii Filatov Co-Founder & CEO, Pink Elephant Group
“As enthusiasm for psychedelic medicine expands, patients face an increasingly complicated environment involving approved treatments, off-label clinical practice, and experimental therapies accessible only via research. Simply locating a provider online reveals little about the regulatory standing, evidence foundation, or protections associated with that care. Transparent, source-based infrastructure that assists individuals in grasping what is genuinely available, and that clearly separates clinical treatment from research involvement, represents a vital move toward safer, more informed, and more equitable access.”
Dr Rayyan Zafar PhD, MRSB, Neuropsychopharmacologist and UKRI Postdoctoral Fellow
“When someone is in distress and cannot identify a clear route, it becomes all too simple to resort to unplanned options out of pure desperation. Mental health care demands a foundation: a coordinated team, a defined ethical structure, and a secure setting. This is not about passing judgment on anyone. It is about acknowledging that assisting vulnerable individuals requires organization and shared expertise.”
Òscar Parés Founder and CEO, Clínica Synaptica
“The past ten years have witnessed a dramatic rise in demand for psychedelic therapies, yet patients frequently have no idea where to seek treatments backed by strong clinical governance. PsyAccess is helping to address that void. With nearly 490 verified providers listed throughout Europe, this serves as an invaluable tool for finding licensed clinics and research facilities. I anticipate that the number of treatment centers will grow significantly in the coming years as psychedelics gain approval, making a free, current directory increasingly valuable.”
Tom McDonald Board member and co-founder, Clerkenwell Health
“As a physician administering ketamine treatments, patient safety and rigorous clinical protocols remain my foremost concerns. Too many individuals seeking psychedelic therapy in Europe end up in unregulated or unverified environments simply because they lack alternative options. A platform like psyaccess.health offers a much-needed medical filter, linking patients to disciplined, professionally overseen care.”
Dr Christopher Gauci MD MRCS(Ed) EDAIC, Anaesthetist and intensive care specialist
PsyAccess also remains remarkably candid about its limitations. It does not rank providers or designate “top” clinics. It makes no assertions about whether treatment is effective. Coverage is sparser in certain nations because access genuinely is, and where a country has two licensed facilities, the directory lists two. All of this is openly stated on the website, not concealed within a disclaimer.
The directory is complimentary, offered in five languages (English, German, Spanish, French, and Polish), and retains no data from its browser-based eligibility assessment unless a user chooses to submit an inquiry. The complete dataset is released openly under CC BY at psyaccess.health/data. Any provider can amend or remove its own entry at psyaccess.health/for-providers. It is active now at psyaccess.health, and the full verification process is publicly available at psyaccess.health/methodology.
About PsyAccess
PsyAccess is a complimentary, registry-verified catalog of licensed esketamine and ketamine treatment, clinical trial locations, and authorized psychedelic-assisted therapy across 27 European nations. Every entry traces back to an official source, includes a last-verified date, and is reassessed on a fixed 90-day schedule. Inclusion verifies licensing and factual assertions against official registries, but never clinical quality, effectiveness, or the therapy itself. Providers incur no fees for listing, and no payment influences inclusion, ranking, or verification. PsyAccess is part of Pink Elephant Group and functions independently within it.
psyaccess.health
Anna Maximova
Pink Elephant Group
a.maximova@pink-elephant.co
Visit us on social media:
LinkedIn
X
Other
